P
Paratek Pharmaceuticals Inc
F:N4CN
Paratek Pharmaceuticals Inc
F:N4CN
Price:
2.024
EUR
Market Closed
Market Cap:
€115.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
P
|
Paratek Pharmaceuticals Inc
F:N4CN
|
US |
|
S
|
Sella Capital Real Estate Ltd
TASE:SLARL
|
IL |
|
Bharatiya Global Infomedia Ltd
NSE:BGLOBAL
|
IN |
|
Saturn Oil & Gas Inc
XTSX:SOIL
|
CA |
|
Oxford BioMedica PLC
LSE:OXB
|
UK |
|
Postmedia Network Canada Corp
TSX:PNC.A
|
CA |
|
1300 Smiles Ltd
ASX:ONT
|
AU |
|
B
|
Beijing Urban-Rural Commercial Group Co Ltd
SSE:600861
|
CN |
|
Bathurst Metals Corp
OTC:BMVVF
|
CA |
|
P
|
Pure Gold Mining Inc
LSE:PUR
|
CA |
|
OIO Holdings Ltd
SGX:KUX
|
SG |
|
H
|
Hoang Kim Tay Nguyen Group JSC
VN:CTC
|
VN |
|
V
|
Vinacomin HaTu Coal JSC
VN:THT
|
VN |
|
Piccadily Agro Industries Ltd
BSE:530305
|
IN |
|
L
|
logly Inc
TSE:6579
|
JP |
|
Clariant AG
OTC:CLZNF
|
CH |
|
P
|
Pertama Digital Bhd
KLSE:PERTAMA
|
MY |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of N4CN.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
N4CN
Multiples-Based Value
Not Available
Multiples Across Competitors
N4CN Competitors Multiples
Paratek Pharmaceuticals Inc Competitors
Paratek Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
P
|
Paratek Pharmaceuticals Inc
F:N4CN
|
115.9m EUR | 0.8 | -2.2 | -8 | -7.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
871.6B USD | 12.9 | 40.8 | 27.6 | 29.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.1B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.4B GBP | 5.2 | 29.7 | 16.4 | 23.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296.9B USD | 4.5 | 15.9 | 9.9 | 12 | |
| CH |
|
Novartis AG
SIX:NOVN
|
230.8B CHF | 5.1 | 20.5 | 12.7 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 11 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
89.3B GBP | 2.7 | 15.2 | 8.2 | 10.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
